The Quiet Crisis of Advanced Stomach Cancer
Every year, more than one million people around the world receive a diagnosis of gastric or gastroesophageal junction (GEJ) adenocarcinoma—what most people simply call stomach cancer or junction cancer where the esophagus meets the stomach. This disease ranks among the top three deadliest cancers globally, with disproportionately poor outcomes once it spreads beyond surgical reach. For patients diagnosed with late-stage, unresectable or metastatic disease, the outlook has long been grim: traditional chemotherapy alone often delivers short-lived tumor shrinkage, and many patients see their cancer grow back within months. Immunotherapy has added meaningful survival gains for some, but not all patients qualify, and responses remain inconsistent across tumor subtypes.
For decades, doctors relied on two core treatment pillars for first-line advanced stomach cancer: platinum-based chemotherapy combinations and PD-1 immune checkpoint inhibitors like pembrolizumab (brand name Keytruda). Yet a large subset of patients still lacked a targeted drug designed specifically for their unique tumor fingerprint. That gap is what the global Phase 3 LUCERNA clinical trial (sponsored by Astellas Pharma) aims to close. LUCERNA tests a three-part treatment cocktail: zolbetuximab (brand name Vyloy), pembrolizumab immunotherapy, and standard chemotherapy. This article breaks down every piece of the story in simple, jargon-free language—starting with the disease itself, the unique tumor biomarkers that make this trial possible, how each treatment works, what the trial structure entails, and why this research could rewrite standard care rules for thousands of stomach cancer patients worldwide.
This guide is written for anyone without medical training: patients weighing trial participation, family caregivers following a loved one’s treatment journey, and curious readers who want to understand how modern precision cancer research works. We will skip dense statistical formulas and overly technical protocol details, focusing instead on real-world meaning, patient experience, and the life-changing potential of this triple therapy combination.
Part 1: Understanding Advanced Gastric & GEJ Adenocarcinoma – Who This Trial Serves
First, we clarify exactly which patients the LUCERNA trial was built to help, and why their disease carries such unique challenges.
What Is Gastric and GEJ Adenocarcinoma?
Adenocarcinoma grows from the thin, glandular lining that coats the inside of the stomach and the gastroesophageal junction (GEJ)—the narrow transition zone where the swallowing tube (esophagus) connects to the stomach. Unlike rare stomach cancer subtypes (such as neuroendocrine tumors), adenocarcinoma accounts for over 90% of all stomach and junction cancer diagnoses. The trial focuses strictly on adults with two high-risk disease stages:
- Locally advanced unresectable: Cancer has spread deep into nearby stomach tissue, lymph nodes, or adjacent organs, but cannot be fully removed with surgery. Tumors may wrap around blood vessels or vital structures, making complete resection impossible without severe, life-threatening damage.
- Metastatic: Cancer cells have broken off from the original stomach/junction tumor and traveled through the bloodstream or lymph system to form new growths in distant organs—most commonly the liver, lungs, bones, or peritoneum (the thin lining around the abdominal cavity).
For both stages, the disease is considered incurable with current standard care, and all treatments focus on three shared goals: extending overall survival time, slowing tumor growth to delay disease worsening, shrinking visible tumors to ease painful symptoms (such as stomach blockages, persistent nausea, or weight loss), and preserving quality of life for as long as possible.
The Three Critical Biomarker Rules for LUCERNA Eligibility
Not every stomach cancer patient qualifies for this trial. To join, a patient’s tumor biopsy must pass three biomarker tests run in a central laboratory using a staining technique called immunohistochemistry (IHC). These three biomarkers divide stomach cancer into distinct subgroups and determine which therapies will work best:
- HER2-negative: The HER2 protein is a tumor growth switch found on roughly 12–13% of stomach cancers. Patients with HER2-positive tumors already have approved targeted antibody treatments (trastuzumab). LUCERNA excludes HER2-positive patients entirely, focusing on the far larger group whose tumors lack this protein and have fewer targeted options.
- CLDN18.2-positive (high expression): Claudin 18.2 (CLDN18.2) is a specialized tight-junction protein that normally only lives on healthy stomach lining cells, acting like a seal between cells to protect the stomach wall from acid damage. When stomach cells turn cancerous, their internal structure breaks apart, pushing massive amounts of CLDN18.2 out onto the tumor cell surface. For trial entry, at least 75% of all tumor cells must show moderate or strong CLDN18.2 staining—this high threshold ensures the targeted drug zolbetuximab has plenty of protein targets to lock onto. Approximately 35–70% of all HER2-negative stomach cancers carry this high CLDN18.2 signature, representing millions of underserved patients globally.
- PD-L1-positive (CPS ≥1): PD-L1 is a protein tumors use to “hide” from the human immune system. It acts like a fake “don’t attack me” signal that silences immune cells trying to kill cancer. The combined positive score (CPS) measures how many immune and tumor cells carry PD-L1. A score of 1 or higher means pembrolizumab immunotherapy has a high chance of reactivating the immune system against the tumor.
In short, LUCERNA enrolls patients with triple-defined tumors: HER2-negative, CLDN18.2-high, PD-L1-positive advanced stomach/GEJ adenocarcinoma. Before this trial, no global Phase 3 research had tested stacking all three therapeutic classes—CLDN18.2 targeted antibody, PD-1 immunotherapy, and chemotherapy—together as first-line treatment for this exact patient group.
Why This Patient Group Faces Major Unmet Medical Needs
Standard first-line treatment for eligible patients before LUCERNA’s launch pairs pembrolizumab immunotherapy with either CAPOX or mFOLFOX6 chemotherapy. This dual combination improves survival compared to chemo alone, but results remain limited for many patients: tumors often progress within 6–8 months, and durable complete remissions (tumors vanishing entirely) are rare.
Zolbetuximab, already approved in Japan as a standalone add-on to chemotherapy, has proven it can lengthen survival when paired only with chemo in earlier global trials (SPOTLIGHT and GLOW). Yet doctors and researchers wondered: could adding pembrolizumab’s immune boost on top of zolbetuximab’s targeted tumor attack create a stronger, longer-lasting anti-cancer effect? LUCERNA exists to answer that pivotal, patient-centric question.
Part 2: Breaking Down the Three Treatments in the LUCERNA Trial – Simple, Patient-Focused Explanations
The trial compares two treatment arms. Every participant receives pembrolizumab plus standard chemotherapy (either CAPOX or mFOLFOX6). The only difference between groups is one extra IV infusion: the experimental arm gets zolbetuximab, while the control arm receives an identical-looking inactive placebo saltwater infusion instead. We explain each therapy separately, using everyday analogies to avoid confusing medical jargon.
- Zolbetuximab (Vyloy): The CLDN18.2 Targeted “Tumor Spotlight” Antibody
Zolbetuximab is a lab-made monoclonal antibody—a synthetic immune protein designed exclusively to bind tightly to exposed CLDN18.2 on cancer cells. Think of it as a glowing sticky tag that only sticks to stomach tumor cells and ignores healthy body cells almost entirely. Its two core anti-cancer actions work hand-in-hand with the body’s natural immune system:
- Immune cell recruitment (ADCC): Once zolbetuximab locks onto CLDN18.2, it signals the body’s natural killer immune cells to rush over and destroy the tagged tumor cell.
- Complement cascade cell death (CDC): The antibody triggers a chain reaction of blood proteins that punch permanent holes in the cancer cell’s outer membrane, causing the cell to rupture and die.
Unlike chemotherapy, zolbetuximab does not attack fast-dividing healthy cells (hair follicles, gut lining, bone marrow), so it causes far fewer traditional chemo side effects like severe hair loss or extreme nausea. It is delivered via slow intravenous (IV) infusion into a vein, either once every two weeks or once every three weeks, depending on the dosing schedule selected by the care team.
Notably, zolbetuximab already holds marketing approval in Japan, making LUCERNA a post-marketing confirmatory study for the Japanese patient population while generating global data for U.S., European, and Asian regulatory bodies like the FDA, EMA, and China’s NMPA.
- Pembrolizumab (Keytruda): The Immune “Brake Release” Immunotherapy
Cancer cells cheat the immune system by displaying PD-L1 protein to switch off attacking immune T-cells. Pembrolizumab is an immune checkpoint inhibitor that blocks the PD-1 receptor on T-cells, removing the tumor’s invisible “stop sign.” Once unblocked, the immune system regains its ability to hunt, shrink, and destroy cancer cells anywhere in the body.
This immunotherapy works through a completely separate pathway from zolbetuximab: zolbetuximab marks tumors for immune elimination, while pembrolizumab unlocks the immune system so it can actually carry out that elimination. Combining the two creates a synergistic “one-two punch”: more immune cells arrive at the tumor site, and those cells are no longer suppressed by the cancer’s PD-L1 shield.
Pembrolizumab is given as an IV infusion either once every three weeks (200mg dose) or once every six weeks (400mg extended dose). Patients can continue receiving pembrolizumab for up to two full years, as long as their cancer does not progress and they tolerate the treatment safely.
- Two Standard Chemotherapy Backbones: CAPOX and mFOLFOX6
All trial participants receive one of two widely accepted first-line chemo regimens, chosen by their treating oncologist based on patient fitness, prior health history, and local clinical practice. Chemotherapy’s core job is to rapidly slow or kill fast-dividing tumor cells to shrink large tumor burdens before the antibody and immunotherapy take full long-term effect. The two options are briefly simplified below:
CAPOX Regimen (Oxaliplatin + Capecitabine)
- Oxaliplatin: Platinum chemo drug given via IV once every three weeks to damage tumor DNA and stop cell division.
- Capecitabine: Oral pill taken twice daily for the first 14 days of each 42-day treatment cycle, then a two-week break. Inside tumor tissue, the pill converts into active fluorouracil chemo to slow growth.
- Key patient benefit: More time at home, fewer weekly hospital visits compared to mFOLFOX6. After eight full chemo cycles, patients drop oxaliplatin and continue only capecitabine maintenance. mFOLFOX6 Regimen (Oxaliplatin + Folinic Acid + 5-Fluorouracil)
- Oxaliplatin: IV infusion every two weeks (lower dose than CAPOX).
- Folinic acid: A vitamin-like booster that amplifies the power of 5-FU.
- 5-Fluorouracil (5-FU): IV chemo given as a quick bolus shot plus a slow continuous infusion.
- Key patient benefit: Powerful tumor-shrinking activity for patients with bulky, fast-growing disease. After 12 chemo cycles, oxaliplatin is stopped, and patients stay on folinic acid + 5-FU maintenance.
Both chemo regimens target rapidly dividing cells, so they carry predictable side effects (fatigue, mild nausea, hand-foot skin sensitivity, nerve cold sensitivity). These side effects are closely monitored throughout the trial and managed with standard supportive care medications.
The Placebo Control: What It Is (and What It Is Not)
The control arm receives a matching placebo IV infusion instead of zolbetuximab. The placebo is simple sterile saltwater (0.9% sodium chloride) with zero anti-cancer ingredients. The infusion bag, tubing, timing, and administration process are identical to zolbetuximab to maintain the trial’s double-blind design—neither the patient nor their treating doctors know which group they are assigned to until the study finishes and data analysis completes.
Critically, every participant in both arms still gets full standard-of-care pembrolizumab + chemotherapy. No patient receives substandard treatment by joining the control group; the trial only tests whether adding zolbetuximab creates extra survival and tumor-shrinking benefits above today’s accepted dual therapy. This ethical design eliminates the major risk many patients fear when considering placebo-controlled cancer trials.
Part 3: Who Can Join LUCERNA? Quick Eligibility
We condense the lengthy formal trial eligibility rules into easy-to-follow bullet points for patients and caregivers reviewing trial participation options.
Core Inclusion Rules (Must Meet All to Screen)
- Age 18 years or older, any gender
- Biopsy-proven stomach or GEJ adenocarcinoma
- Radiology scans confirming locally advanced unresectable OR metastatic disease, completed within 28 days before screening
- Tumor biomarker results: HER2-negative, ≥75% CLDN18.2 membrane staining (moderate/strong), PD-L1 CPS ≥1
- ECOG performance status 0 or 1 (able to complete most daily activities independently)
- Predicted minimum remaining lifespan of at least 12 weeks
- Eligible to receive either CAPOX or mFOLFOX6 chemo plus pembrolizumab per standard guidelines
- Strict adherence to contraception rules for men and women of childbearing age during treatment and for months after final doses
- No participation in other interventional experimental cancer trials while receiving LUCERNA study drugs Part 4: Why LUCERNA Matters – Real-World Impact for Global Stomach Cancer Care
- Fills a Critical Clinical Knowledge Gap
Prior trials separately validated zolbetuximab + chemo and pembrolizumab + chemo as effective first-line options for distinct patient subsets. No large global Phase 3 study had yet tested stacking all three treatment modalities together for the triple biomarker-positive patient group defined in LUCERNA. If the trial hits its primary survival endpoint, it will establish a new triple therapy standard of care for thousands of patients who currently only receive dual chemo-immunotherapy. - Supports Global Regulatory Approval Across Regions
The trial runs simultaneous enrollment across the U.S., Europe, Asia, Latin America, and Australia, generating diverse racial, ethnic, and regional patient data that every major drug regulator (FDA, EMA, NMPA China, PMDA Japan) requires to approve new combination therapies. Japanese sites contribute post-marketing confirmatory data for zolbetuximab’s existing Japanese approval label, while Chinese trial sites feed data to China’s national clinical trial registry (CTR20253090) for domestic reimbursement and approval pathways. - Expands Precision Medicine for Underserved Patient Populations
CLDN18.2-positive stomach cancer affects high rates of patients in East Asia (China, Japan, South Korea), regions with among the world’s highest stomach cancer incidence and mortality rates. LUCERNA’s multi-Asian trial sites ensure research captures treatment responses specific to Asian patient populations, reducing the historic gap in diverse cancer trial representation. - Provides Long-Term Safety Data for Combined Triple Therapy
Combining three powerful anti-cancer treatments raises natural questions about overlapping side effects and long-term organ risks. LUCERNA’s multi-year follow-up window (up to six years) will capture rare, delayed adverse events that shorter Phase 2 trials cannot detect, giving oncologists clear safety guidance for long-term real-world administration if the regimen is approved. - Empowers Patients Through Biomarker Testing Awareness
Beyond treatment outcomes, LUCERNA raises public and clinical awareness of mandatory triple biomarker testing (HER2, CLDN18.2, PD-L1) for all newly diagnosed advanced stomach cancer patients. Many patients currently only receive HER2 testing; this trial underscores why CLDN18.2 and PD-L1 screening unlock access to potentially life-extending targeted and immune therapies. Part 5: Frequently Asked Patient Questions (Simplified)
Q1: If I join the trial, could I receive only placebo and miss the new targeted drug?
A: Every participant receives full standard-of-care pembrolizumab + chemotherapy, the current accepted first-line treatment worldwide. The only difference is the addition of zolbetuximab or matching saltwater placebo. You will never receive chemo alone or immunotherapy alone without chemotherapy—all patients get the full dual therapy backbone regardless of group assignment. Q2: How long will I need to stay on trial treatment if I enroll?
A: Treatment continues until your cancer progresses, side effects become unmanageable, or you choose to stop therapy. Pembrolizumab can be given for a maximum of two years, while chemotherapy cycles are limited to 8 CAPOX cycles or 12 mFOLFOX6 cycles before switching to maintenance single-agent chemo. Even after stopping treatment, you will complete years of follow-up scans and health checks to contribute long-term survival data. Q3: Are trial visits and study medications free for participants?
A: All trial-related testing, infusions, scans, and biomarker lab work are covered by the trial sponsor Astellas Pharma. Standard routine medical costs unrelated to trial procedures remain the responsibility of the patient or their insurance plan, consistent with standard global clinical trial rules. Q4: Can I leave the trial at any time if I change my mind?
A: Yes. Patients retain full voluntary rights to withdraw from LUCERNA at any point, with no penalty or impact on their standard cancer care from their oncology team. The care team will review alternative approved treatment options if you decide to discontinue trial participation. Q5: When will the trial results become public?
A: Full data collection will finish in September 2028, with primary survival analysis published shortly after database lock. Interim safety data may be shared at major global oncology conferences (ASCO, ESMO) before full study completion, giving the public early insight into treatment tolerability and preliminary tumor response rates. Conclusion: LUCERNA – Building a Brighter Treatment Future for CLDN18.2-Positive Stomach Cancer
For decades, advanced stomach cancer carried a devastating prognosis, with limited tools to extend survival beyond months for most patients. The arrival of targeted CLDN18.2 antibodies like zolbetuximab and PD-1 immunotherapy pembrolizumab has rewritten that narrative—but until LUCERNA, researchers lacked definitive large-scale data proving whether combining all three treatment classes delivers superior survival benefits over today’s standard dual therapy.
This global Phase 3 trial stands at the intersection of precision targeted therapy, immune checkpoint activation, and traditional chemotherapy, designed specifically for the large subset of HER2-negative, CLDN18.2-high, PD-L1-positive stomach and GEJ adenocarcinoma patients who still face limited treatment options. For patients considering trial enrollment, LUCERNA offers access to a potentially transformative triple therapy regimen while contributing vital research that will shape global stomach cancer treatment guidelines for decades to come.
As the trial continues active recruitment across dozens of countries through 2028, patients, caregivers, and clinicians alike will watch its outcomes closely. If successful, LUCERNA will establish a new gold-standard first-line triple therapy, offering longer survival, deeper tumor shrinkage, and sustained symptom relief to millions of people living with late-stage stomach cancer worldwide.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoRelated Clinical Trials
A Predictive Model Based on Narrow Band Imaging for Early Gastric Cancerous Lesions
Without high diagnostic efficacy of endoscopic forceps biopsy (EFB) and with low diagnostic efficacy of narrow band imaging (NBI) in novice endoscopists and endoscopists of community hospitals in China, it is urgent to improve diagnostic efficacy for gastric cancerous lesions.The investigators will conduct a study to develop and validate a diagnostic model based on NBI for early gastric cancerous lesions under endoscopic observation.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer
Claudin 18.2 is a promising therapeutic target overexpressed on the surface of gastric cancer cells. The addition of zolbetuximab, the monoclonal antibody targeting Claudin 18.2 to chemotherapy in two recent Phase 3 studies prolonged survival outcomes, indicating that Claudin 18.2 is a valid target in gastric cancer. Asan Medical Center researchers conducted a study on Claudin 18.2 expression in patients with operable gastric cancer and defined moderate to strong claudin expression in more than 75% of tumor cells as Claudin 18.2 overexpression, which was observed in 46.5% of patients with stage I-III tumors. This suggests that zolbetuximab-based treatment may be possible in patients with LAGC. Therefore, The investigator designed a prospective, multicenter, open-label, Phase Ib/II study to determine the efficacy and safety of zolbetuximab/DOS as neoadjuvant chemotherapy in patients with LAGC.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study of TAVO412 in Patients with Cancer (TAVO412)
TAVO412 Phase 1 is an open-label, non-randomized, 2-part Phase I study to examine the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of TAVO412. Part 1 will utilize a standard 3 + 3 design to determine the MTD/RP2D of TAVO412 in subjects with advanced or metastatic solid tumors who progressed on prior approved standard of care therapy. Part 2 will further evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and pharmacologic activity of TAVO412 in a new set of subjects with advanced or metastatic gastric cancer, non-small cell lung cancer (NSCLC), or subjects of other solid tumor types with best clinical responses (e.g., CR \> PR \> SD) from Part 1 that progressed on prior approved standard of care therapy.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoEfficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)
The main objective of this study is to evaluate the efficacy and safety of IV FCM(ferric carboxymaltose) in patients with AGC receiving palliative chemotherapy. This study will also evaluate the effect of IV FCM on the treatment outcomes of palliative chemotherapy in patients with gastric cancer receiving fluoropyrimidine and platinum-based regimen in the same 1st-line palliative setting.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoThe Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer
This study is a prospective, dual arm, open Ib/II phase clinical trial, with the main objective of exploring the safety and efficacy of Adebrelimab combined with Apatinib and Lrinotecan liposome for second-line treatment of advanced gastric cancer. The study is divided into two stages. The first stage is the safety introduction period, which includes 6 patients. Observe whether the subjects experience dose limiting toxicity (DLT) during the observation period. If no subjects experience DLT during the observation period, the study enters the next stage. The dose of Lrinotecan liposome used during the safety introduction period is 80mg/m2, and the DLTs observation period is 1 cycle. If the patient cannot tolerate it, the dose will be reduced to 60mg/m2. In the second stage, advanced gastric cancer subjects who have progressed to first-line treatment will be included in two cohorts: those who have previously received immune checkpoint inhibitor therapy and have first-line PFS\>7m (cohort 1) and those who have received standard systemic chemotherapy (cohort 2). 30 subjects will be included in each population, and a total of 66 subjects are planned to be enrolled. The study includes a screening period (from the signing of the informed consent form by the subjects to the first treatment, not exceeding 28 days), a treatment period (Adebrelimab combined with Apatinib and Lrinotecan liposome), and a follow-up period (including safety and survival follow-up).
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoAdebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
This study employs a randomized, controlled, exploratory clinical trial design, with a planned enrollment of 66 patients who have previously failed systemic chemotherapy for recurrent/metastatic gastric cancer,
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoInvestigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer
The study aims to evaluate the safety and benefits of using indocyanine green in lymph node dissection for gastric cancer surgery. The primary endpoint is the average number of lymph nodes removed. Secondary study points are the average number of ICG-positive lymph nodes; the average number of metastatic ICG-positive lymph nodes; the number of postoperative complications and complications associated with the administration of ICG. Patients who meet the inclusion criteria for this study will be enrolled in the study after reviewing and signing an informed consent form. All patients will be included in one group and will receive surgical treatment in the amount of total or subtotal gastrectomy with lymphadenectomy D1, D1+, D2 or D2+. ICG is injected by the patient by endoscopic submucosal injection into 4 points around the tumor 24-12 hours before the start of the surgical intervention. Assessment of the number of fluorescent lymph nodes will be performed intraoperatively with their subsequent removal and mapping. The incidence of postoperative complications will be assessed by Clavien-Dindo.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoOGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
Abstract Background Our previous studies have shown OGT method significantly simplified overlap esophagojejunostomy with good short-term outcomes, and provided new perspectives for optimizing esophagojejunostomy. However, the safety and efficiency of OGT method still need evidence of randomized controlled trial. Methods: This trial is a prospective, multicenter, randomized, controlled, open, and superiority trial. Three hundred and forty-four patients who met the inclusion criteria and did not accord with the exclusion criteria will be randomly divided into OGT group(n=172) and traditional group(n=172). The primary purpose of this study is to evaluate time of oesophagojejunostomy of OGT method compared with traditional method for Siewert III/II esophagogastric junction cancer and gastric cancer. The second purpose is to evaluate the success rate of inserting anvil fork into esophageal lumen at first attempt, attempts of inserting anvil fork into esophagus, early postoperative complications,recovery course and compare the postoperative hospital stay of the patients enrolled in this study. Discussion: This trial is the first prospective randomized two-arm controlled study to determine the safety and efficiency of OGT method compared with traditional overlap method. Through this trial, we hope to show that experienced surgeons can safely perform OGT-assisted overlap esophagojejunostomy for Siewert III/II esophagogastric junction cancer and gastric cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoPerioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
For locally advanced gastric and gastroesophageal junction adenocarcinoma (cT3-4bNanyM0), perioperative PD-1 antibody combined with chemotherapy can downstage tumor stage, increase the R0 resection rate, and may improve the long-term survival. Combination of perioperative surufatinib, sintilimab and chemotherapy for locally advanced gastric and gastroesophageal junction adenocarcinoma could be a novel therapeutic strategy to increase response rate and therapeutic efficacy. Surufatinib, as the oral drug in this study is a small molecule kinase inhibitor that mainly acts on vascular growth factor receptor (VEGFR1, 2,3), fibroblast growth factor receptor 1(FGFR1) and colony stimulating factor 1 receptor (CSF1R). It is a proprietary product developed by Hutchison Whampoa Pharmaceutical (Shanghai, China) Co., LTD. Surufatinib has been approved for neuroendocrine tumor. This study is a monocenter, single-arm phase 2 clinical trial to evaluate tolerability, safety and efficacy of perioperative surufatinib in combination with sintilimab and chemotherapy in locally advanced gastric and gastroesophageal junction adenocarcinoma.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoNeoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Neoadjuvant radiotherapy plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoExploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen
it is an an Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination with SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoDocetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
This is a multi-center, non-randomized, 3-cohort, phase II trial, evaluating a triplet combination of docetaxel, oxaliplatin and fluorouracil for gastric cancer with peritoneal carcinomatosis and inoperable malignant bowel obstruction.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoRadiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of radiotherapy combined with chemotherapy and anti-PD-1 immunotherapy followed by surgery for the primary and metastatic lesions in patients with limited metastatic gastric or gastroesophageal junction adenocarcinoma. The main questions it aims to answer are: 1) If the multimodal treatment which includes anti-PD-1 immunotherapy and local therapies will improve the survival of this group of patients. 2) If the multimodal treatment which includes anti-PD-1 immunotherapy and local therapies can be performed safely in this group of patients. Participants will receive short course hypofractionated radiotherapy (HFRT) for the primary lesion, HFRT or stereotactic body radiotherapy (SBRT) for metastatic lesions, combined with systemic chemotherapy and anti-PD-1 immunotherapy. For patients with HER2-positive cancer (defined as IHC 3+ or 2+/ISH+), trastuzumab is used along with chemotherapy and anti-PD-1 antibody. Then, surgical resections of primary and metastatic lesions are performed as much as possible. For patients who need a widely invasive surgical approach or are inoperable, local ablative therapies such as radiofrequency ablation (RFA) and microwave ablation (MVA) can be alternatives. For patients undergoing surgical resections, postoperative treatment includes chemotherapy, which is determined by the researcher, and PD-1 antibody, which will be maintained until one year after surgery.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoEvaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer
Purpose of the study To evaluate whether the clinical efficacy of submucosal injection of indocyanine green tracer laparoscopic gastric cancer lymph node dissection is superior to that of laparoscopic gastric cancer lymph node dissection without indocyanine green tracer in 3D fluorescence laparoscopic mode in patients with gastric adenocarcinoma (cT1-4a, N-/+, M0). To observe the role of submucosal injection of ICG for tumor localization in fluorescence 3D fluorescence laparoscopic surgery and the application of lymph node dissection in laparoscopic radical surgery for gastric cancer. Study design. Multicenter, randomized, open, parallel-controlled, superiority design. Subgroups Group A (experimental group): indocyanine green tracer 3D laparoscopic gastric cancer lymph node dissection group Group B (control group): no indocyanine green tracer 3D laparoscopic gastric cancer lymph node dissection group. Study population Patients who met all the inclusion criteria and did not fall into any of the exclusion criteria were eligible to enter this study. Randomization Patients were first evaluated preoperatively to determine that they could receive laparoscopic radical gastric cancer treatment and receive endoscopic indocyanine green labeling. Once the enrolled cases were determined to meet the admission criteria after laparoscopic exploration, they could be enrolled in this study for randomization. The central dynamic, stratified zone randomization method was used in this study, and the control factors considered were age, tumor site, and preoperative stage. Given the number of seeds and the length of the zones, SAS 9.2 programming was applied to generate the treatment allocation corresponding to the running number 484, which was deposited in the data center. A person at the participating research center was responsible for sending the enrolled case information (age, tumor site, and preoperative stage) to the randomization implementation department at the data center by email, phone, or SMS, and the contact person at each respective research center confirmed that the patient met the enrollment criteria, contacted the contact person for the assigned case in this study, and determined the enrollment of the case by further analyzing the case information, and at the same time, notified the contact person at the research center where the case was located The contact person of the research center where the case is located will be notified at the same time. Competitive enrollment was used in this study. Blinding.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
To observe and evaluate the efficacy and safety of adebrelimab combination chemotherapy regimen in the perioperative treatment of surgically resectable gastric cancer/adenocarcinoma of the gastroesophageal junction.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoClinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer
To explore the efficacy and safety of Fruquintinib combined with Sintilimab and XELOX in the first-line treatment of unresectable advanced metastatic gastric or gastroesophageal junction adenocarcinoma.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoSafety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
This is a multi-center, prospective, open label phase 2 study evaluating the safety and efficacy of standard first-line chemotherapy XELOX regimen combined with Sintilimab (anti-PD-1 antibody) and Lenvatinib in the treatment of advanced AFP-positive gastric cancer. This study was conducted in the Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital. Previous phase 1 dose escalation study (TJMUCH-GI-GC002) has demonstrated that such combinational pattern was well tolerated with promising efficacy. In this study, patients with AFP-positive and HER-2-negative advanced gastric cancer who had not received palliative systematic treatment in the past will be enrolled. Patients who met the inclusion criteria were treated with XELOX regimen combined with Sintilimab plus Lenvatinib every 3 weeks until disease progression or intolerable adverse reactions or death. The treatment regimen is XELOX chemotherapy (oxaliplatin 130mg/ m2, d1, capecitabine 850-1250 mg/m2, bid, d1-14, every 3 weeks) in combination with Sintilimab (\>=60kg, 200 mg; \<60kg, 3mg/kg; intravenous infusion, every 3 weeks) plus Lenvatinib (determined from previous phase 1 study, 16mg, orally once a day). Patients received regular and periodic reviews, with imaging evaluations every 6 weeks. Safety will be evaluated by AE and laboratory tests.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoOral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoOrgan Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with chemoradiation is an efficient and safe treatment option for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery.
PDF$29 only! Buy Clinical Trial Full Report With Contact Info